Improve It is being conducted by some top researchers, including Harvard University's Eugene Braunwald and Duke University's Robert Califf .

FORBES: Merck, Schering Launch Huge Heart-Drug Test

The drug giant convened the ten-member panel, headed by Eugene Braunwald of Harvard Medical School in Boston, to examine the safety of heart-failure treatment Natrecor.

FORBES: Magazine Article

Eugene Braunwald, a prominent Harvard cardiologist who is running a Vytorin trial, called Peto "the best statistician in the universe" while telling reporters that any cancer risk with the drug is unlikely.

FORBES: Magazine Article

Eugene Braunwald of Harvard University, who chaired the panel, and Wilson S. Colucci of Boston University, who served on it, say they would support tightening the FDA's labeling of Natrecor to prevent injudicious use of the drug.

FORBES: Cardiologist Calls For Limits On J&J Drug

Harvard's Eugene Braunwald, one of the most well regarded cardiologists in the country, said that an analysis of the data hadn't given a safety committee reason to stop a large study of Vytorin and Zocor that he is running, called IMPROVE-IT.

FORBES: Another Blow For Merck And Schering